Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter.

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the activist investor’s unfolding proxy fight. Starboard stopped short of ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Activist investor Starboard is backing down in its fight at Pfizer after seeing little chance of winning board seats or rousing enough shareholder pressure to force out its CEO. A deadline to ...

Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting in April, Damian Garde and Crystal Tse of ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. NOW OPEN ...

Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter. Starboard did not nominate any directors ...

(Bloomberg) -- Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter. Starboard did not nominate ...